| |
Overalla (N = 258)
|
Control (N = 62)
|
Snus trial (N = 64)
|
Nicorette trial (N = 67)
|
Ariva trial (N = 65)
|
|---|
|
Bid Snus
|
US$1.00
|
US$0.72
|
US$0.60
|
US$1.55b
|
US$1.13
|
|
(1.86)
|
(1.12)
|
(0.98)
|
(1.53)
|
(1.90)
|
|
Bid Nicorette
|
US$1.87
|
US$2.04
|
US$1.54
|
US$1.87
|
US$2.03
|
|
(2.62)
|
(2.23)
|
(2.23)
|
(3.13)
|
(2.78)
|
|
Bid Ariva
|
US$1.40
|
US$1.44
|
US$0.91
|
US$1.78
|
US$1.47
|
|
(1.92)
|
(1.42)
|
(1.42)
|
(2.11)
|
(2.42)
|
|
Bid Cigarettes
|
US$4.06
|
US$4.09
|
US$3.30
|
US$4.16
|
US$4.76
|
|
(2.34)
|
(1.84)
|
(1.89)
|
(4.09)
|
(2.44)
|
- (Standard deviations in parentheses)
- Difference in bids for those who tried snus vs. those who chose not to try snus is statistically significant at the 5 % level
-
aDifferences in bids across all four products are statistically significant at the 5 % level using a 2-sided t test
-
bDifferences in bids for snus in the group that received the snus trial and those that received the Nicorette trial are statistically significant at the 5 % level using a 2-sided t test
